These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19948455)

  • 1. Management of vascular endothelial growth factor and multikinase inhibitor side effects.
    Wood LS
    Clin J Oncol Nurs; 2009 Dec; 13 Suppl():13-8. PubMed ID: 19948455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
    Eisen T; Sternberg CN; Robert C; Mulders P; Pyle L; Zbinden S; Izzedine H; Escudier B
    J Natl Cancer Inst; 2012 Jan; 104(2):93-113. PubMed ID: 22235142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapeutic strategies for renal cell carcinoma.
    Wood LS
    Urol Nurs; 2010; 30(1):40-53. PubMed ID: 20359144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
    Rini BI
    Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Renal cell carcinoma management and therapies in 2010].
    Albouy B; Gross Goupil M; Escudier B; Massard C
    Bull Cancer; 2010; 97():17-28. PubMed ID: 20418201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Ravaud A; Sire M
    Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
    Hutson TE; Figlin RA; Kuhn JG; Motzer RJ
    Oncologist; 2008 Oct; 13(10):1084-96. PubMed ID: 18838439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cutaneous side effects of sorafenib and sunitinib].
    Autier J; Mateus C; Wechsler J; Spatz A; Robert C
    Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of mTOR inhibitor side effects.
    Creel PA
    Clin J Oncol Nurs; 2009 Dec; 13 Suppl():19-23. PubMed ID: 19948456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
    Fléchon A; Boyle H; Négrier S
    Bull Cancer; 2010; 97():73-82. PubMed ID: 20418206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
    Bukowski RM
    Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
    [No Abstract]   [Full Text] [Related]  

  • 13. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Targeted therapies: sequential and combined treatments].
    Gross-Goupil M; Escudier B
    Bull Cancer; 2010; 97():65-71. PubMed ID: 20418205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cutaneous side effects of antiangiogenic agents].
    Robert C
    Bull Cancer; 2007 Jul; 94 Spec No():S260-4. PubMed ID: 17846013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
    Staehler M; Haseke N; Schöppler G; Stadler T; Heinemann G; Stief CG
    Urologe A; 2006 Oct; 45(10):1333-42; quiz 1343. PubMed ID: 17021905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing adverse events associated with sorafenib in renal cell carcinoma.
    Edmonds K; Spencer-Shaw A
    Br J Nurs; 2010 Jan 14-27; 19(1):58-60. PubMed ID: 20081715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From theoretical synergy to clinical supra-additive toxicity.
    Soria JC; Massard C; Izzedine H
    J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
    [No Abstract]   [Full Text] [Related]  

  • 19. New therapeutic options for renal cell carcinoma.
    Stadler W
    Clin Adv Hematol Oncol; 2006 Jun; 4(6):429-30. PubMed ID: 16981664
    [No Abstract]   [Full Text] [Related]  

  • 20. [Advanced renal carcinomas with special situations. How to treat them?].
    Pouessel D; Patard JJ; Culine S
    Bull Cancer; 2010; 97():83-90. PubMed ID: 20418207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.